Novartis (NVS) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St turns lower as crude spikes, chip stocks weigh
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Novartis (NVS) slides as Q4 EPS, revenue miss estimates
January 31, 2024 7:30 AM ESTNovartis (NYSE: NVS) stock fell 4% in premarket trading Wednesday after the Swiss pharmaceutical company reported worse-than-expected core earnings for the fourth quarter.
Concretely, Novartis posted Q4 core earnings per share (EPS) of $1.53, missing the consensus projection of $1.66. Revenue came in at $11.42 billion, also below the estimated... More



